Luxturna
NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy
September 4, 2019Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma
NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
Spark hands over Luxturna rights outside US to Novartis for $170m
January 25, 2018Sales and Marketing Luxturna, Novartis, Spark Therapeutics, pharma
Novartis has confirmed a deal worth a potential $170 million with Spark Therapeutics to develop and commercialise its gene therapy …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
August 14, 2026
